[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
News From the Food and Drug Administration
June 2, 1999

Orlistat Approved for Obesity

Author Affiliations

Not Available

Not Available

JAMA. 1999;281(21):1978. doi:10.1001/jama.281.21.1978

The FDA has approved orlistat (Xenical, Hoffmann-La Roche, Nutley, NJ) for obesity management, including weight loss and weight maintenance, when used in conjunction with a reduced-calorie diet. The product is also indicated to reduce the risk for weight regain after weight loss. It is indicated for obese patients with an initial body mass index of at least 30 kg/m2 or at least 27 kg/m2 in the presence of other risk factors (eg, hypertension, diabetes, or dyslipidemia).